ERBB2 and breast carcinoma: To determine the suitability of the current standard HER2 IHC assays for identifying patients with HER2-low breast cancers, a concordance survey of 18 pathologists reading 170 breast cancer biopsies was carried out (Fernandez et al., 2022).